Pharmacogenomics Corner

Back to articles

Genotype-guided warfarin dosing resulted in better outcomes in elective surgical procedures

November 20, 2017

Advising on this article:
Mary W. Roederer

Email this article

KEY POINT

Genotype-guided warfarin dosing for patients undergoing elective hip or knee arthroplasty resulted in a reduced risk of the composite of major bleeding, elevated international normalized ratio (INR), venous thromboembolism (VTE), or death compared with clinically guided dosing, according to results of the Genetic Informatics Trial (GIFT) published in JAMA.

SOURCES

Gage BF, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. JAMA. 2017;318(12):1115–24.

Emery JD, et al. Pharmacogenomic testing and warfarin: what evidence has the GIFT trial provided? JAMA. 2017;318(12):1110–2.

Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):398–404.

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.